Ocugen CEO to Address Gene Therapy Commercialization
Alpha Vantage · MyChesCo · · AI-summarised by FinFlash
Ocugen CEO Shankar Musunuri will participate in a panel discussion at the Cell & Gene Meeting on the Mesa 2026 in Phoenix to discuss regulatory approval and commercialization of cell and gene therapies. The Malvern-based biotechnology company is advancing gene-agnostic treatments for inherited retinal diseases and other causes of blindness, including retinitis pigmentosa, Stargardt disease, and geographic atrophy. The conference aims to address development and commercialization challenges in the cell and gene therapy industry.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.